본문
SEOUL, Korea – L&C Bio (KOSDAQ: 290650) announced its participation as a major sponsor at the 2023 2nd Symposium of the Korean Society of Cartilage and Osteoarthritis (KSCO), held at the Ambassador Seoul Pullman Hotel from October 19–20.
During the event, L&C Bio showcased a range of its core and new products at its exhibition booth. Highlights included MegaDerm®, MegaDBM®, MegaBone®, STENInject®, MegaDerm® XE, PION® Low-Dose CT, and newly launched products such as MegaCarti® and MegaNerve Prime®.
At the Luncheon Symposium, Professor Min Jung of Severance Hospital presented on the clinical effectiveness and superiority of MegaCarti®, a newly released product designed for knee cartilage regeneration. MegaCarti® recently received conditional approval through Korea’s New Health Technology Assessment (nHTA) deferment program, allowing non-reimbursed clinical use in university and orthopedic specialty hospitals starting this month.
A company spokesperson stated:
“With the establishment of L&C Medicare earlier this year, we are accelerating our expansion into the orthopedic sector.”
The Korean Society of Cartilage and Osteoarthritis (KSCO) is a professional academic organization focused on research related to cartilage and osteoarthritis. It originated as a study group in 2007 and officially launched as a society in 2017.
